Ipca Labs - Soft Q2, Near-Term Growth Challenges: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Ipca Laboratories Ltd. delivered a significant beat across parameters driven by sharp improvement across domestic businesses in Q2 FY22. Revenue beat estimates by 5% at Rs 15.2 billion.

Ipca Labs’ end to end integration (61% of sales) enables it to benefit significantly despite inflationary raw material prices as gross margins declined 100 basis points at 64% though margins at 24% were in-line with our estimate despite higher selling general and administrative spend.

Further, basis the strong traction seen across segments, it retained its guidance 9-10% growth in top-line for FY22E.

Impacted by Covid-19, commercialisation of its greenfield facility at Dewas and brownfield expansion of its active pharma ingredient facility at Ratlam are expected to commercialise by FY23E and Q3 FY22 respectively.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.